



Your Dreams, Our Challenge

Summit for Innovative Drug Discovery AGC's initiatives as a CDMO

AGC Inc.
30th July 2024




Key strengths of AGC's Life Science Business

- Biotechnology-related R&D began in the 1970s, and CDMO* business expanded in earnest in 2010s
- Acquired US and EU's CDMO and mega-pharma's facilities, which have extensive experience including commercial ones, and then completed global integration

1. Providing a high standard of services integrated from 10 sites in three regions of Japan, the United States and Europe

Build an advanced cGMP system. Provide the equivalent high standard of development and manufacturing services in a wide range of modalities from any of these regions.



2. Extensive Manufacturing and Inspection Track Record

Based on many years of business experience, we have accumulated extensive manufacturing and inspection track records, and have gained our customers' trust.


		FDA (U.S.)	EMA (EU)	PMDA (Japan)
Small molecule	Japa (Chiba)	●		●
	Spain	●	●	●
Biopharmaceuticals	U.S.	●	●	●
	Denmark	●	●	●
	Germany	●	●	●
	Italy	●	●	
	Japan(Chiba)			●

Build cutting-edge and one of the largest CDMO site in Japan


- One of the largest* CDMO facilities in Japan is under construction in Yokohama, combining track records achieved globally.
- Adopted as “Dual-use Subsidy” from METI (Services will begin sequentially from 2025)



Multiple and cutting-edge modalities



mAb



Cell Therapy



mRNA



Combine extensive knowledge cultivated in Japan, the United States and Europe




Development and manufacturing organization with 400 talents in a location with excellent access



* The largest class of mammalian cell culture bioreactors as a CDMO in Japan (AGC estimate) is to be introduced.

AGC's role in “Innovative Drug Discovery Ecosystem”

- Contribute to the formation and enhancement of a Japanese “Innovative Drug Discovery Ecosystem” that can be competitive globally.



Appendix




Business Overview

FY2023 Sales (Billion Yen)

AGC Group

2019.3 billion yen




Main Life Science businesses

Business Domain	Service Overview	FY2023 Sales Breakdown
Biopharmaceuticals CDMO	<ul style="list-style-type: none">Contract development and manufacturing of biopharmaceuticals (microbial, mammalian cell culture, gene and cell therapy, pDNA, mRNA, exosomes)	<ul style="list-style-type: none">+/-70%
Small molecule pharmaceuticals and agrochemicals CDMO	<ul style="list-style-type: none">Contract development and manufacturing of small molecule pharmaceuticalsContract development and manufacturing of agrochemicals	<ul style="list-style-type: none">+/-30%

Expansion of manufacturing and development technologies

- Since acquiring BIOMEVA in 2016, AGC has expanded its business regionally and technologically through substantial capital expenditures and M&As, forming a solid foundation as a pharmaceutical CDMO.
- Now, building on this foundation, further expanding in the cell & gene therapy area.



Disclaimer:

- This material is solely for information purposes and should not be construed as a solicitation. Although this material (including the financial projections) has been prepared using information we currently believe reliable, AGC Inc. does not take responsibility for any errors and omissions pertaining to the inherent risks and uncertainties of the material presented.
- We ask that you exercise your own judgment in assessing this material. AGC Inc. is not responsible for any losses that may arise from investment decisions based on the forecasts and other numerical targets contained herein.
- Copyright AGC Inc. No duplication or distribution without prior consent of AGC Inc



Your Dreams, Our Challenge